BioSpace News Archive

Nektar Therapeutics announced that biomarker and clinical data from PIVOT-02 is being presented at the 2019 American Society of Clinical Oncology Meeting in Chicago, Illinois.

Moderna, Inc. announced interim data from an ongoing Phase 1 clinical study in patients with both resected (adjuvant) and unresected (advanced) solid tumors.

Five Prime Therapeutics, Inc. presented monotherapy data from the dose escalation portion of the Phase 1a/1b clinical trial of FPA150 in patients with advanced solid tumors.

Counseling and resources available free-of-charge to local community

Novartis announced statistically significant overall survival results for Kisqali in combination with endocrine therapy

Intensity Therapeutics, Inc. announced positive preliminary results from the company’s ongoing Phase 1/2 clinical trial of its lead product candidate, INT230-6, in a poster at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Clovis Oncology, Inc. announced multiple datasets being presented at the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, May 31 – June 4, 2019.

Longest Follow-Up Data for KEYTRUDA in Lung Cancer to Date Showed Five-Year Overall Survival Rate of 23.2% with KEYTRUDA in Treatment-Naïve Patients and 15.5% in Previously Treated Patients with Advanced NSCLC in KEYNOTE-001 Trial

Sierra Oncology, Inc. reported positive preliminary clinical data from its two first-in-human Phase 1/2 studies of SRA737, a highly selective oral Chk1 inhibitor, as monotherapy and as SRA737+LDG (SRA737 potentiated by low dose gemcitabine), at the 2019 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

Caris Next Generation Profiling™ enables a proprietary algorithm to accurately classify tumors, demonstrating improvement in cancer diagnosis